To take advantage of this technology, we performed targeted NGS with a gene panel covering 416 cancer-related genes to profile genetic characteristics of 83 non-small cell lung cancer (NSCLC) patients after they developed systematically progress to the first generation EGFR TKI treatments, including erlotinib, gefitinib and icotinib. Here, EGFR is linked to cancer.